Summary by Futu AI
Anson Funds Management LP and its affiliates have reported beneficial ownership of 113,479 shares of Transcode Therapeutics common stock, representing a 0.9% stake. The position includes shares underlying warrants subject to a 9.99% ownership limitation.The shares are held through a private fund co-advised by Anson Funds Management LP and Anson Advisors Inc. Voting and disposition rights are shared among Tony Moore as principal of Anson Funds Management, and Amin Nathoo and Moez Kassam as directors of Anson Advisors Inc. The total share calculation is based on 1,029,095 outstanding shares as of February 4, 2024, plus 106,838 shares receivable upon warrant exercise.
Comment(0)
Reason For Report